Overview: 5-FU Toxicity DPD Mutation TestIntroduction: The 5-FU Toxicity DPD Mutation Test detects genetic variants in the DPYD gene that affect dihydropyrimidine dehydrogenase (DPD) activity, linked to severe toxicity from 5-Fluorouracil (5-FU), a chemotherapy drug, causing side effects like nausea or low blood counts. Aligned with 2023 CPIC guidelines, it uses PCR for high accuracy, ensuring safe 5-FU dosing. This test is vital for identifying at-risk patients, adjusting chemotherapy regimens, and preventing life-threatening side effects, improving outcomes in oncology pharmacogenetics.
Other Names: DPD Gene Assay, DPYD Genotyping Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards.
Historical Milestone: DPD mutations were linked to 5-FU toxicity in the 1990s. PCR-based genotyping emerged in the 2000s, and by the 2010s, guidelines recommended DPYD testing for safe chemotherapy.
Purpose: Identifies DPD mutations to guide safe 5-FU dosing and prevent toxicity in cancer patients.
Test Parameters: 1. DPD Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report planned 5-FU therapy or prior chemotherapy toxicity.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs, or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours at room temperature to preserve DNA.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen, as DNA may degrade.
Medical History: Document planned 5-FU therapy, prior chemotherapy toxicity, or family history of drug metabolism issues. Include cancer type and treatment history.
Consent: Written consent is required, explaining the test's purpose, pharmacogenetic implications, and potential chemotherapy adjustments.
Procedural Considerations: Employs PCR to detect DPYD mutations. Results are delivered in 3-5 days due to the complexity of genetic analysis.
Factors Affecting Result Accuracy: Low DNA yield or contamination may cause false results. Rare variants or mosaicism can lead to misinterpretation.
Clinical Significance: DPYD mutations indicate a high risk of 5-FU toxicity, necessitating dose reduction or alternative therapy. Normal genotypes suggest standard dosing is safe.
Specialist Consultation: Consult an oncologist or pharmacogeneticist for result interpretation. Genetic counseling is advised for familial implications.
Additional Supporting Tests: DPD enzyme activity assay or 5-FU therapeutic monitoring to confirm toxicity risk.
Test Limitations: Rare DPD variants may be missed. Non-genetic factors affecting DPD activity require clinical correlation.
References: CPIC DPYD Guidelines, 2023; Amstutz U, Clinical Pharmacology & Therapeutics, 2022.
